{"id":"stable-haart","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Stable HAART involves the combination of multiple antiretroviral drugs to suppress HIV-1 replication, thereby preventing the progression of the disease. This approach aims to maintain viral loads below detectable levels, reducing the risk of transmission and complications associated with HIV-1 infection.","oneSentence":"Stable HAART refers to a long-term antiretroviral therapy regimen that maintains viral suppression in HIV-1 infected patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:07.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT03149211","phase":"PHASE3","title":"To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults","status":"WITHDRAWN","sponsor":"United BioPharma","startDate":"2025-04-01","conditions":"HIV-1 Infection","enrollment":""},{"nctId":"NCT00107549","phase":"PHASE1","title":"Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT01098045","phase":"","title":"HIV Fat Redistribution and the Evaluation of Brown Fat","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-03","conditions":"HIV Infections","enrollment":27},{"nctId":"NCT04138199","phase":"","title":"A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation","status":"TERMINATED","sponsor":"AbbVie","startDate":"2019-11-01","conditions":"HIV-1 Infection","enrollment":239},{"nctId":"NCT00842634","phase":"PHASE1","title":"Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-01","conditions":"HIV, HIV Infections","enrollment":12},{"nctId":"NCT01426243","phase":"PHASE3","title":"The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2011-07","conditions":"HIV Infection, Yellow Fever","enrollment":71},{"nctId":"NCT00987948","phase":"PHASE2","title":"Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2010-01","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00867854","phase":"","title":"Treatment De-Intensification and Residual HIV-1 in Youth","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-02","conditions":"HIV-1, HIV Infections","enrollment":34},{"nctId":"NCT00232908","phase":"PHASE4","title":"QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"HIV Infections","enrollment":361},{"nctId":"NCT00562510","phase":"PHASE3","title":"Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery","status":"TERMINATED","sponsor":"Pedro Cahn","startDate":"2008-08","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT01307124","phase":"PHASE3","title":"Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-03","conditions":"HIV-infected Children","enrollment":199},{"nctId":"NCT01250899","phase":"NA","title":"Vitamin D in HIV-Infected Patients on HAART","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2010-10","conditions":"Vitamin D Deficiency, HIV","enrollment":122},{"nctId":"NCT00450320","phase":"PHASE1","title":"Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-10","conditions":"Sarcoma","enrollment":7},{"nctId":"NCT01805427","phase":"","title":"Antiretroviral Therapy and Extreme Weight","status":"COMPLETED","sponsor":"Hopital Lariboisière","startDate":"2012-09","conditions":"HIV Infection","enrollment":140},{"nctId":"NCT00622206","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Low Dose Ritonavir","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-01","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT00757250","phase":"PHASE1","title":"Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy","status":"TERMINATED","sponsor":"US Biotest, Inc.","startDate":"2008-09","conditions":"HIV Infections","enrollment":13},{"nctId":"NCT00772902","phase":"PHASE4","title":"ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-10","conditions":"HIV-1","enrollment":85},{"nctId":"NCT00985543","phase":"PHASE1","title":"Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-10","conditions":"Acquired Immunodeficiency Syndrome","enrollment":22},{"nctId":"NCT00067795","phase":"","title":"Evaluating Immune Function Tests in People With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00615810","phase":"PHASE4","title":"ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-03","conditions":"HIV Infections","enrollment":159},{"nctId":"NCT00528892","phase":"PHASE3","title":"Switching From PI to RALtegravir in HIV Stable Patients","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2008-01","conditions":"HIV Infections","enrollment":282},{"nctId":"NCT00343941","phase":"PHASE2","title":"Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11","conditions":"HIV Infection","enrollment":45},{"nctId":"NCT00643968","phase":"PHASE4","title":"Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-03","conditions":"HIV Infections","enrollment":140},{"nctId":"NCT00433056","phase":"PHASE3","title":"Long Term Treatment Interruptions","status":"COMPLETED","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2004-01","conditions":"HIV Infections, AIDS","enrollment":320},{"nctId":"NCT00195312","phase":"PHASE1","title":"Study Evaluating Vaccine in Adults With HIV","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-08","conditions":"HIV Infections","enrollment":91},{"nctId":"NCT00195234","phase":"PHASE1","title":"Study Evaluating Vaccine in Adults With HIV","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-12","conditions":"HIV Infections","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"stable HAART","genericName":"stable HAART","companyName":"A.O. Ospedale Papa Giovanni XXIII","companyId":"a-o-ospedale-papa-giovanni-xxiii","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Stable HAART refers to a long-term antiretroviral therapy regimen that maintains viral suppression in HIV-1 infected patients. Used for Treatment of HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}